Clinicians offering early access to Grail’s multi-cancer early detection (MCED) test are now waiting for the full NHS trial readout after an endpoint miss. Providers and researchers are weighing whether the remaining evidence is sufficient ahead of an expected FDA regulatory decision. The controversy centers on the trial limitations that surfaced before the complete dataset release, creating a practical gap between patient demand for earlier detection and the evidentiary bar required for wider uptake. The discussion also reflects how MCED studies are still evolving on acceptable performance metrics. For developers, this episode underscores that regulatory pathways for population-scale screening technologies hinge not just on innovation but on trial endpoints, analytical interpretation, and how regulators weigh sensitivity, specificity, and downstream clinical impact.